ARTICLE | Tools & Techniques

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Durable pharmacodynamic data in non-human primates sets up Verve’s path to the clinic in 2022

January 13, 2021 1:10 AM UTC

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack.

Six-month data shared by Verve Therapeutics Inc. Tuesday showed that in four cynomolgus monkeys, lead candidate VERVE-101 induced and sustained an 89% reduction in plasma levels of target protein PCSK9, and a 61% drop in low-density lipoprotein cholesterol (LDL-C), which drives heart attack and stroke following accumulation in the arteries. ...

BCIQ Company Profiles

Verve Therapeutics Inc.